Immunocore Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/22
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022GlobeNewsWire • 08/03/22
Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/02/22
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022GlobeNewsWire • 08/01/22
Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 29%: Read This Before Placing a BetZacks Investment Research • 07/25/22
Here's Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Great Momentum Stock to BuyZacks Investment Research • 07/08/22
Wall Street Analysts See a 36% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?Zacks Investment Research • 07/08/22
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™GlobeNewsWire • 06/25/22
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanomaGlobeNewsWire • 06/08/22
Wall Street Analysts See an 80% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?Zacks Investment Research • 06/06/22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/06/22
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi's product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanomaGlobeNewsWire • 06/03/22
Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/26/22
Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New ZealandPRNewsWire • 05/23/22
Immunocore Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/11/22